Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study.
Saved in:
| Title: | Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study. |
|---|---|
| Authors: | Yu, Jie-Hai1 (AUTHOR), Xiao, Bin-Yi1 (AUTHOR), Li, Dan-Dan1,2 (AUTHOR), Jiang, Wu1 (AUTHOR), Ding, Ya2 (AUTHOR), Wu, Xiao-Jun1 (AUTHOR), Zhang, Rong-Xin1 (AUTHOR), Lin, Jun-Zhong1 (AUTHOR), Wang, Wei3,4 (AUTHOR), Han, Kai1 (AUTHOR), Kong, Ling-Heng1 (AUTHOR), Zhang, Xin-Ke5 (AUTHOR), Chen, Bi-Yun6 (AUTHOR), Mei, Wei-Jian1 (AUTHOR), Pan, Zhi-Zhong1 (AUTHOR), Tang, Jing-Hua1 (AUTHOR), Zhang, Xiao-Shi1,2 (AUTHOR), Ding, Pei-Rong1 (AUTHOR) dingpr@sysucc.org.cn |
| Source: | Lancet Oncology. Jul2024, Vol. 25 Issue 7, p843-852. 10p. |
| Database: | Academic Search Ultimate |
| ISSN: | 14702045 |
|---|---|
| DOI: | 10.1016/S1470-2045(24)00203-1 |
